RE:RE:RE:RE:Not one comment in favor of the merger..."Question I have why do CEOs make so much money if they can't accomplish any goals."
Everything is still in place and with the merger CZO's near-term revenue generating pipeline is expected to be fully financed. The merger established an exchange ratio but the ultimate value of the merged company will only be determined upon events. Gilles is inside both companies and has Ronnie Miller by his side. That said, this is a risky microcap and there are no guarentees.
This daisy chain of news may be released after the clouds around the merger are resolved and on NASDAQ with analyst support. What is the target price?
The path,
the daisy chain of events that will define this merger...
AEZS's diagnostic test clinical trial results for children
Launch of powder formulations of CZO's two active ingredients(beta glucan, avenanthramide)
CZO's main client returns
AEZS's diagnostic continuing roll-out for adults
FDA approval for the test for children
Licensing deal for the diagnostic test for North America
Commissioning of 5X PGX scale-up
Commissioning of 10X scale-up to decision point for mass industrialization of PGX
PGX licensing deal
Immune booster plant
Phase I avenanthramide clinical trial results
Wound healing results
Wound healing partnership
Fibrosis clinical trial 'go'/'no go' decision and regulatory filing
Phase IIa avenanthramide clinical trial results
Avenanthramide pill partnership
AIM Biologicals 'go'/'no go' clinical trial decision